<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624437</url>
  </required_header>
  <id_info>
    <org_study_id>CHNiort</org_study_id>
    <nct_id>NCT05624437</nct_id>
  </id_info>
  <brief_title>BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus</brief_title>
  <acronym>BESST</acronym>
  <official_title>BElimumab corticoSteroids Sparing Treatment in Systemic Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Niort</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de Niort</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BELIMUMAB, anti-BLyS human monoclonal antibody, is the first immunotherapy used for the&#xD;
      treatment of systemic lupus erythematosus (SLE) which was licensed in 2011 in France.&#xD;
&#xD;
      Currently, Belimumab is reimbursed for the treatment of active SLEwith autoantibody-positive&#xD;
      after intolerant or initial failure of first-line traitment (anti malaria, non-steroidal&#xD;
      anti-inflammatory drugs, glucocorticoids and/ou immunomodulatory agents).&#xD;
&#xD;
      EUropean League Against Rheumatism (EULAR) suggest the following terminology of &quot;low dose&quot;&#xD;
      when steroids are less than 7.5 mg/day (prednisone equivalent) because this dose range is&#xD;
      often used for maintenance therapy for many rheumatic diseases requiring glucocorticoids and&#xD;
      it is relatively few adverse effects.&#xD;
&#xD;
      In patients with SLE, a significant proportion of the damage could be attributed to&#xD;
      corticosteroid therapy, and this damage accumulated over time.&#xD;
&#xD;
      Thanks to randomised and subgroups trials, post-hoc analysis , BELIMUMAB seems to be&#xD;
      interesting in the maintain of lowest possible dose of glucocorticoids. However, these&#xD;
      studies were not design with this aim, so it is impossible to conclude.&#xD;
&#xD;
      Thus, BELIMUMAB seems to be very interesting treatment to redcuce glucocorticoids level.&#xD;
&#xD;
      We conduce a multicentric French study in real-life settings, to assess the ability of&#xD;
      belimumab to achieve low-dose of steroids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2021</start_date>
  <completion_date type="Actual">August 31, 2022</completion_date>
  <primary_completion_date type="Actual">November 19, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>number of patients whith low dose of steroids at six months after BELIMUMAB</measure>
    <time_frame>at six months after BELIMUMAB</time_frame>
    <description>number of patients whith low dose of steroids at six months after BELIMUMAB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients whith low dose of steroids at 12, 18 and 24 months after BELIMUMAB</measure>
    <time_frame>12, 18 and 24 months after BELIMUMAB</time_frame>
    <description>number of patients whith low dose of steroids at 12, 18 and 24 months after BELIMUMAB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative dose of steroids at 6, 12, 18, 24 months</measure>
    <time_frame>6, 12, 18, 24 months</time_frame>
    <description>cumulative dose of steroids at 6, 12, 18, 24 months</description>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>SLE (Systemic Lupus)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data record</intervention_name>
    <description>data record</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        person aged ≥ 18 years&#xD;
&#xD;
          -  with SLE according to ACR/EULAR criteria 2019&#xD;
&#xD;
          -  started treatment by BELIMUMAB between 13 / July / 2011 to 13 / July / 2020&#xD;
&#xD;
          -  following in an hospital center in Poitiers, La Rochelle, Rochefort, Niort, Angoulême,&#xD;
             Nantes, Rennes, Tours, Angers&#xD;
&#xD;
          -  affiliate or beneficiary of a social security scheme&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  person aged ≥ 18 years&#xD;
&#xD;
          -  with SLE according to ACR/EULAR criteria 2019&#xD;
&#xD;
          -  started treatment by BELIMUMAB between 13 / July / 2011 to 13 / July / 2020&#xD;
&#xD;
          -  following in an hospital center in Poitiers, La Rochelle, Rochefort, Niort, Angoulême,&#xD;
             Nantes, Rennes, Tours, Angers&#xD;
&#xD;
          -  affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons Under guardianship or curatorship or without civil law&#xD;
&#xD;
          -  Pregnant and breastfeeding&#xD;
&#xD;
          -  Persons who refused to participate&#xD;
&#xD;
          -  Patients who stoppped BELIMUMAB before 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier de Niort</investigator_affiliation>
    <investigator_full_name>Perier</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

